Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

The global metastatic colorectal cancer (mCRC) market is expanding rapidly, fueled by rising colorectal cancer cases, therapy advancements, and a focus on patient outcomes. mCRC, a severe cancer form, ...

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic colorectal cancer, phase 3 data show.

Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib) in combination with ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Akeso initiates patient enrolling in phase III trial of ivonescimab for first-line treatment of advanced metastatic colorectal cancer: Hong Kong Thursday, July 17, 2025, 13:00 Hrs ...

Marwan G. Fakih, MD, discusses the top takeaways from using combination treatment in metastatic colorectal cancer.

According to a new comprehensive report from The Insight Partners, the global colorectal cancer treatment market is observing significant growth owing ...

Clinical study in Scientific Reports shows Bridge CaptureTM detects key mutations from blood samples in metastatic colorectal cancer patients ...

Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generation sequencing ...

Anita Turk, MD, discusses what she is most excited about regarding immunotherapy in the realm of colorectal cancer treatment.

Genomill Health’s Bridge Capture technology detects key mutations from blood samples in metastatic colorectal cancer patients: Turku, Finland Wednesday, July 16, 2025, 18:00 Hrs ...